In silico design of colchicine-based bioisosteric inhibitors of tubulin for the treatment of rheumatoid arthritis

  • Authors:
    • Li Wang
    • Hao‑Jie Yang
    • Ran Tu
    • Min Shen
    • Dan Liu
  • View Affiliations

  • Published online on: August 9, 2017     https://doi.org/10.3892/mmr.2017.7202
  • Pages: 4823-4828
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The super-saturation of serum with monosodium urate due to hyperuricemia is the core metabolic disorder of rheumatoid arthritis. When the serum urate concentration is ≥7 mg/dl, this results in the crystallization of monosodium urate in serum at body temperature (37˚C/98.6˚F). Colchicine (COL) is considered to be a first‑line medication for acute arthritis when NSAIDs are contraindicated. COL causes severe side effects, including diarrhea, nausea, cramping, abdominal pain and vomiting, in humans. Experimental studies have additionally demonstrated the presence of mutagenic and reproductive effects in humans. In the present study, molecular docking simulation techniqueswere used to design COL‑derived bioisosteric inhibitors, with the aim of designing an alternative treatment that exhibitedpotent anti‑arthritic activity and was free from the side effects associated with COL.

Related Articles

Journal Cover

October-2017
Volume 16 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Yang HJ, Tu R, Shen M and Liu D: In silico design of colchicine-based bioisosteric inhibitors of tubulin for the treatment of rheumatoid arthritis. Mol Med Rep 16: 4823-4828, 2017
APA
Wang, L., Yang, H., Tu, R., Shen, M., & Liu, D. (2017). In silico design of colchicine-based bioisosteric inhibitors of tubulin for the treatment of rheumatoid arthritis. Molecular Medicine Reports, 16, 4823-4828. https://doi.org/10.3892/mmr.2017.7202
MLA
Wang, L., Yang, H., Tu, R., Shen, M., Liu, D."In silico design of colchicine-based bioisosteric inhibitors of tubulin for the treatment of rheumatoid arthritis". Molecular Medicine Reports 16.4 (2017): 4823-4828.
Chicago
Wang, L., Yang, H., Tu, R., Shen, M., Liu, D."In silico design of colchicine-based bioisosteric inhibitors of tubulin for the treatment of rheumatoid arthritis". Molecular Medicine Reports 16, no. 4 (2017): 4823-4828. https://doi.org/10.3892/mmr.2017.7202